MyFinsight
Home
About
Contact
abus: the income statement
Download
Download image
Comprehensive loss
-$7,684K
(60.59%↑ Y/Y)
Unrealized gain on
available-for-sale securities
$58K
(-73.39%↓ Y/Y)
Interest income
$952K
(-45.51%↓ Y/Y)
Net loss
-$7,742K
(60.73%↑ Y/Y)
Total other income
$917K
(-46.78%↓ Y/Y)
Non Cash Royalty
$249K
Collaboration And Contracts
$280K
Foreign exchange (loss)
gain
-$12K
(-340.00%↓ Y/Y)
Interest expense
$23K
(-20.69%↓ Y/Y)
Loss from operations
-$8,659K
(59.61%↑ Y/Y)
Revenues
$529K
(-60.49%↓ Y/Y)
Total operating
expenses
$9,188K
(-59.66%↓ Y/Y)
Restructuring costs
$98K
(-97.30%↓ Y/Y)
Change in fair value of
contingent consideration
$268K
(-22.09%↓ Y/Y)
General and
administrative
$3,044K
(-32.91%↓ Y/Y)
Research and development
$5,778K
(-59.52%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (ABUS)